Equities analysts forecast that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will report $45.88 million in sales for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Alnylam Pharmaceuticals’ earnings, with the highest sales estimate coming in at $56.70 million and the lowest estimate coming in at $38.80 million. Alnylam Pharmaceuticals posted sales of $29.91 million during the same quarter last year, which suggests a positive year-over-year growth rate of 53.4%. The company is scheduled to issue its next earnings results on Thursday, August 1st.
According to Zacks, analysts expect that Alnylam Pharmaceuticals will report full-year sales of $185.52 million for the current year, with estimates ranging from $113.10 million to $236.00 million. For the next fiscal year, analysts anticipate that the company will report sales of $420.05 million, with estimates ranging from $307.77 million to $514.80 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($1.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.20) by $0.47. Alnylam Pharmaceuticals had a negative net margin of 929.51% and a negative return on equity of 55.33%. The company had revenue of $33.29 million for the quarter, compared to the consensus estimate of $21.60 million. During the same period in the previous year, the business earned ($1.22) EPS. The company’s revenue was up 52.0% on a year-over-year basis.
Several brokerages have issued reports on ALNY. Zacks Investment Research downgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, April 9th. Leerink Swann boosted their target price on shares of Alnylam Pharmaceuticals to $90.00 and gave the company a “market perform” rating in a research note on Tuesday, April 9th. BMO Capital Markets boosted their target price on shares of Alnylam Pharmaceuticals from $106.00 to $119.00 and gave the company an “outperform” rating in a research note on Tuesday, April 9th. Cantor Fitzgerald reissued a “buy” rating and set a $135.00 target price on shares of Alnylam Pharmaceuticals in a research note on Tuesday, April 9th. Finally, Svb Leerink boosted their target price on shares of Alnylam Pharmaceuticals from $65.00 to $70.00 and gave the company a “market perform” rating in a research note on Tuesday, April 9th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and fifteen have assigned a buy rating to the company’s stock. Alnylam Pharmaceuticals has an average rating of “Buy” and an average price target of $130.24.
Shares of NASDAQ:ALNY opened at $68.07 on Thursday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 9.12 and a current ratio of 9.33. Alnylam Pharmaceuticals has a 12-month low of $60.27 and a 12-month high of $124.21. The firm has a market cap of $7.33 billion, a price-to-earnings ratio of -8.99 and a beta of 2.53.
In other news, Director Philip A. Sharp sold 15,000 shares of the business’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $88.23, for a total transaction of $1,323,450.00. Following the transaction, the director now directly owns 250,633 shares in the company, valued at approximately $22,113,349.59. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 3.60% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. Royal London Asset Management Ltd. boosted its holdings in Alnylam Pharmaceuticals by 16.7% in the fourth quarter. Royal London Asset Management Ltd. now owns 66,803 shares of the biopharmaceutical company’s stock worth $4,703,000 after purchasing an additional 9,566 shares in the last quarter. Gateway Investment Advisers LLC boosted its holdings in Alnylam Pharmaceuticals by 17.3% in the fourth quarter. Gateway Investment Advisers LLC now owns 4,531 shares of the biopharmaceutical company’s stock worth $330,000 after purchasing an additional 667 shares in the last quarter. Meeder Asset Management Inc. boosted its holdings in Alnylam Pharmaceuticals by 332.9% in the first quarter. Meeder Asset Management Inc. now owns 342 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 263 shares in the last quarter. Frontier Capital Management Co. LLC boosted its holdings in Alnylam Pharmaceuticals by 3,071.0% in the fourth quarter. Frontier Capital Management Co. LLC now owns 197,869 shares of the biopharmaceutical company’s stock worth $14,427,000 after purchasing an additional 191,629 shares in the last quarter. Finally, Coronation Fund Managers Ltd. bought a new stake in Alnylam Pharmaceuticals in the first quarter worth $11,789,000. Institutional investors and hedge funds own 87.89% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.
Read More: How is an ETF different from a mutual fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.